Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Payne reported the recent EU approval of KOSTAIVE, Arcturus' self-amplifying mRNA COVID-19 vaccine, and receipt of an initial milestone payment from CSL. He announced an upcoming marketing ...

High in the southern sky around 10 P.M. local daylight time is the constellation Coma Berenices. Look for it to the upper ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

ARCTURUS THERAPEUTICS ($ARCT) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.52 per share, beating estimates of -$1.36 by ...

Arcturus Therapeutics shares have fallen 32% since the beginning of the year. In the final minutes of trading on Monday, shares hit $11.60, a drop of 57% in the last 12 months.

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a ...